For Patients and Caregivers
Instead of your doctor choosing a treatment based on the average patient, we test more than 150 FDA-approved drugs and combinations directly against your specific cancer cells.
For Physicians
Discover how we combine live-cell drug sensitivity testing, DNA/RNA sequencing, and an individualized machine-learning model to help identify drugs and combinations specifically for each person’s unique biology.
For Industry
An entirely new lens for drug development, target identification, and biomarker discovery, validated for 52 cancer types and counting across both solid and hematologic cancers.
Real-World Impact
83%
of patients achieved an objective response when care decisions were guided by our insights
8.5x
Longer progression-free survival
relative to previous therapy, as demonstrated in a peer-reviewed study*
IN 10 DAYS
We aim to deliver personalized insights
*n=6
See firsthand how First Ascent helped Logan’s fight against acute myeloid leukemia.
Validated by scientific publications and strengthened through collaborations with top-tier cancer treatment centers and academic medical institutions nationwide, these results demonstrate the promise of our approach in treating the most challenging cancers.
